First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16 VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy…
Takeda, a major pharmaceutical company, has released promising results from a Phase 4 clinical trial titled VERDICT. The trial, conducted in adults with moderate to severe ulcerative colitis, compared two treatment approaches: achieving corticosteroid-free (CSF) disease clearance versus achieving corticosteroid-free symptomatic remission.
The findings revealed that the CSF disease clearance group experienced a significantly longer time to their first UC-related complication, with a hazard ratio of 0.33 (95% confidence interval 0.17-0.67). This means that patients who achieved CSF disease clearance were at nearly 70 percent lower risk of UC complications compared to those who only achieved symptomatic remission.
The trial provides the first randomized evidence that achieving disease clearance is a viable and clinically significant target in the treatment of moderate to severe ulcerative colitis. The results were presented at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
